KaloBios Pharma (KBIO) Announces Filing of 10-Q, 10-K for 2015
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
KaloBios Pharmaceuticals, Inc. (OTC: KBIO) announced the filing with the U.S. Securities and Exchange Commission (SEC) of the company’s Form 10-Q for the three and nine months ended September 30, 2015, and its Form 10-K for the fiscal year ended December 31, 2015.
The filings mark an important step towards the achievement of one of the company’s key near-term goals of regaining compliance with periodic reporting requirements of the SEC and to seek relisting on a national securities exchange.
“Our momentum continues to build due to our intense focus on executing our strategic priorities,” said Cameron Durrant, MD, KaloBios chairman and CEO. “We intend to be back in compliance with our filings as expeditiously as possible, as we also work to strengthen our financial position and accelerate our pipeline programs.”
KaloBios emerged from bankruptcy on June 30, 2016, with new management and a transformational strategy, including the Responsible Pricing Model.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ReWalk Robotics (RWLK) Plans Offering of Ordinary Shares and Warrants
- Philip Morris (PM) Discloses Formal Probe Related to PM Thailand in 10-Q Filing
- NCI, Inc. (NCIT) Reports $63M Army Task Order
Create E-mail Alert Related CategoriesCorporate News, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!